MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with A

Alimemazine

Alimemazine 10mg tablets

Use with caution

Stability notes for Alimemazine 10mg tablets

Alimemazine powder may darken on exposure to light.

Provenance

This compatibility recommendation is derived from Alimemazine 10mg tablets (Zentiva Pharma UK Ltd).

Suppliers (6) of Alimemazine 10mg tablets
Alimemazine 10mg tablets (A A H Pharmaceuticals Ltd)
Alimemazine 10mg tablets (Alliance Healthcare (Distribution) Ltd)
Alimemazine 10mg tablets (Key Pharmaceuticals Ltd)
Alimemazine 10mg tablets (Medihealth (Northern) Ltd)
Alimemazine 10mg tablets (Phoenix Healthcare Distribution Ltd)
Alimemazine 10mg tablets (Zentiva Pharma UK Ltd)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.